Cerenome is trading at $1.44, down 9.8% after hours, with no clear company-specific catalyst identified. - It closed at $1.60 on October 2, 2026; supplied price context shows the October 2 close was down 10.11%. - Cerenome updated its CNS oncology investor presentation that morning. On October 1, Lake Street cut its price target from $50 to $31, maintaining a Buy rating; neither report explicitly links these developments to the after-hours move. - Major U.S. indices were higher, and no after-hours volume was reported, leaving the decline unexplained.